Longeveron Inc.LGVNEarnings & Financial Report
Longeveron Inc. is a clinical-stage biotechnology company specializing in regenerative medicine therapies for aging-related and life-threatening conditions. Its lead candidate targets geriatric frailty, Alzheimer's disease, and cardiovascular disorders, with core operations focused on the U.S. biopharmaceutical market.
LGVN Q4 FY2025 Key Financial Metrics
Revenue
$365.0K
Gross Profit
$257.0K
Operating Profit
$-5.4M
Net Profit
$-5.4M
Gross Margin
70.4%
Operating Margin
-1479.2%
Net Margin
-1491.5%
YoY Growth
-39.5%
EPS
$-0.23
Longeveron Inc. Q4 FY2025 Financial Summary
Longeveron Inc. reported revenue of $365.0K (down 39.5% YoY) for Q4 FY2025, with a net profit of $-5.4M (down 33.3% YoY) (-1491.5% margin). Cost of goods sold was $108.0K, operating expenses totaled $5.7M.
Key Financial Metrics
| Total Revenue | $365.0K |
|---|---|
| Net Profit | $-5.4M |
| Gross Margin | 70.4% |
| Operating Margin | -1479.2% |
| Report Period | Q4 FY2025 |
Longeveron Inc. Annual Revenue by Year
Longeveron Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.2M).
Longeveron Inc. Quarterly Revenue & Net Profit History
Longeveron Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $365.0K | -39.5% | $-5.4M | -1491.5% |
| Q3 FY2025 | $137.0K | -82.3% | $-7.2M | -5270.8% |
| Q2 FY2025 | $316.0K | -32.5% | $-5.0M | -1591.1% |
| Q1 FY2025 | $381.0K | -30.5% | $-5.0M | -1315.2% |
| Q4 FY2024 | $603.0K | +857.1% | $-4.1M | -677.1% |
| Q3 FY2024 | $773.0K | +415.3% | $-4.4M | -571.7% |
| Q2 FY2024 | $468.0K | +115.7% | $-3.4M | -729.3% |
| Q1 FY2024 | $548.0K | +96.4% | $-4.1M | -740.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $548000 | $468000 | $773000 | $603000 | $381000 | $316000 | $137000 | $365000 |
| YoY Growth | 96.4% | 115.7% | 415.3% | 857.1% | -30.5% | -32.5% | -82.3% | -39.5% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $9.7M | $19.4M | $29.9M | $25.6M | $20.8M | $16.7M | $15.6M | $10.3M |
| Liabilities | $6.7M | $4.5M | $4.3M | $3.7M | $3.7M | $4.1M | $5.6M | $4.6M |
| Equity | $3.0M | $14.9M | $25.6M | $21.9M | $17.2M | $12.7M | $10.0M | $5.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-3.1M | $-4.6M | $-2.8M | $-3.4M | $-4.7M | $-3.6M | $-5.1M | $-5.3M |